Relay Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information
Rule 10b5-1 Trading Plans
The following table describes, for the three month period ended June 30, 2026, each trading arrangement for the sale or purchase of our securities adopted, materially modified, orterminatedby our directors and officers that is a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, or a Rule 10b5-1 Trading Arrangement. No other officers or directors adopted, materially modified, or terminated a Rule 10b5-1 Trading Arrangement or any non-Rule 10b5-1 trading arrangement during the three month period ended June 30, 2026.
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Expiration Date | Aggregate Number of Securities |
|---|---|---|---|---|
| Mark Murcko (Director) | Adoption (06/04/2026) | Rule 10b5-1 Trading Arrangement | The earlier of (i) 03/31/2027 and (ii) the completed sale of the maximum shares subject to the plan. | Up to 75,000 Shares |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.